新型冠状病毒主蛋白酶抑制剂的研究进展  

Advances in research of coronavirus main protease inhibitors

作　　者：解春雨 刘兆鹏[1] 李荀 XIE Chun-yu;LIU Zhao-peng;LI Xun(Institute of Medicinal Chemistry chool of Pharmaceutical Sciences,Shandong University Ji'nan 250012,China;School of Pharmaceutical Science and Technology Shandong First Medical University&Shandong Academy of Medical Sciences,Jinan 250117 China)

机构地区：[1]山东大学药学院药物化学研究所,山东济南250012 [2]山东第一医科大学/山东省医学科学院药物科学与技术学院,山东济南250117

出　　处：《中国药物化学杂志》2022年第7期548-559,共12页Chinese Journal of Medicinal Chemistry

摘　　要：新型冠状病毒感染所引起的疫情给世界造成了严重的破坏,尽管已经开发出了疫苗,但仍需要抗病毒药物来对抗新型冠状病毒的感染。新型冠状病毒主蛋白酶[M^(pro),也称为类3C蛋白酶(3CL^(pro))]在进化过程中高度保守,在调控冠状病毒RNA复制中具有重要的生物学功能,已成为研发新型广谱抗冠状病毒药物有吸引力的药物靶标。本文对M^(pro)的分子结构及其抑制剂的研究进展进行了综述,以期为靶向M抗新型冠状病毒药物的研发提供有益的借鉴和参考。The epidemic caused by the new coronavirus(COVID-19) infection has caused serious damage to the world, although effective vaccines have been rapidly developed, antiviral drugs are still needed to combat the new coronavirus infection.SARS-CoV-2 main protease(M^(pro),also known as 3 C-like protease, 3 CL^(pro)) is highly conserved in the evolution process and plays an important biological role in regulating the replication of coronavirus RNA,making it an attractive drug target for novel broad-spectrum anti-coronavirus drugs.This article reviews the research progress of the molecular structure of Mand its inhibitors, in order to provide useful references for the development of anti-new coronavirus drugs targeting M^(pro).

关 键 词：新型冠状病毒 主蛋白酶 抑制剂 研究进展 

分 类 号：R914[医药卫生—药物化学]